Previous 10 | Next 10 |
ROCKAWAY, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth quarter and year ended December 31, 2022, after the close of the market on Wedn...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips With major economic weakness possibly lurking around the corner, investors should consider targeting stocks to sell. Specifically, market participants should note securities that feature rising short borrow fees. As the name su...
ROCKAWAY, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced an agreement with Byond Healthcare Pty Ltd. to serve as the exclusive distributor of gammaCore Sapphir...
ROCKAWAY, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents and intends to issue a third new patent related to ...
ROCKAWAY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-15. The reverse stock s...
electroCore ( NASDAQ: ECOR ) stock rises 9.5% with Q4 and FY guidance, expects FY 2022 revenue o f ~$8.5M ( vs. consensus $8.2M ), representing 68% growth Y/Y. Government Channels: For the FY of 2022, the company expects to recognize revenue of ~$5.1M pursuant to the D...
Record revenue of approximately $2.5 million for the three months ended December 31, 2022 and $8.5 million for full-year 2022 Revenue growth of approximately 57% over full-year 2021 Launched two new brands; TAC-STIM ™ under the Air Force BOOST program and Truvaga ...
electroCore ( NASDAQ: ECOR ) launches a new wellness product offering called Truvaga for customers residing in the United States. Truvaga is a handheld non-invasive vagus nerve stimulator that utilizes our proven technology to quickly and gently activate the vagus nerve ...
ROCKAWAY, N.J., Dec. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic company, today announced the launch of a new wellness product offering called Truvaga TM for customers residing in the United States. The new wellness product is offered throug...
ROCKAWAY, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents related to its non-invasive vagus nerve stimulation (nVNS) techn...
News, Short Squeeze, Breakout and More Instantly...
ROCKAWAY, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is thrilled to announce the Commercial Off the Shelf (COTS) availability of the next generation TAC-STIM™, a non-invasive vagus nerve stimulat...
2024-06-11 04:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
ROCKAWAY, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced the closing of its previously announced registered direct offering of 22...